Quoin Pharmaceuticals Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment

The late-stage specialty pharmaceutical company developing treatments for rare and orphan diseases Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), announced a robust start to 2025 with significant clinical, corporate, and financial milestones highlighted in its Q1 results.

During the first quarter, Quoin reported encouraging data from multiple studies of its lead asset, QRX003, for the treatment of Netherton Syndrome (NS). Key findings included nearly complete skin healing, elimination of pruritus, and the discontinuation of prior medications in pediatric patients receiving whole-body treatment. However, follow-up data showed a reversal of these benefits upon stopping treatment, reinforcing the drug's mechanism of action and the need for continuous therapy.

CEO Dr. Michael Myers emphasized the promising results and expanding impact of the company's efforts. "In short, this has been a busy but highly productive start to 2025, and we are very excited by our continued progress and remain focused on delivering the first approved treatment for this devastating disease."

The company also expanded its intellectual property portfolio, filing patents for novel topical formulations targeting additional rare dermatological conditions such as microcystic lymphatic malformations, venous malformations, and angiofibromas. In February, Quoin launched NETHERTON NOW, a new awareness initiative aimed at educating and supporting the NS community and healthcare stakeholders.

From a financial standpoint, cash and equivalents totaled $11.6 million as of March 31, 2025, and are expected to fund operations into Q1 2026. Net loss for the quarter was $3.8 million, up from $2.3 million in Q1 2024, reflecting increased R&D investment.

Quoin plans to expand its clinical footprint with new QRX003 studies, including a recently FDA-cleared trial led by Dr. Amy Paller at Northwestern University. This study will evaluate whole-body use of the treatment in up to 12 patients, generating the most comprehensive dataset yet for Netherton Syndrome.

The post Quoin Pharmaceuticals Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment appeared first on PRISM MarketView.

COMTEX_465479733/2927/2025-05-13T12:02:51